Please provide your email address to receive an email when new articles are posted on . In female-to-male transgender patients, subcutaneous testosterone therapy was safe and effective and was the ...

Contraindications to the use of exogenous testosterone formulations, which are Schedule III controlled substances, include prostate cancer (PCa), breast cancer, and/or untreated prolactinoma. 5 TRT ...

Please provide your email address to receive an email when new articles are posted on . Laurenzano, Marinkovic and colleagues conducted a retrospective study analyzing subcutaneous testosterone as ...

EWING, N.J.--(BUSINESS WIRE)--Antares Pharma, Inc. (NASDAQ: ATRS) today announced positive results from a multi-center phase 2 clinical study evaluating the pharmacokinetic profile of testosterone ...

Antares Pharma, Inc. has reported positive results from a multi-centre phase II clinical study evaluating the pharmacokinetic profile of testosterone enanthate administered once-weekly by subcutaneous ...

The US Food and Drug Administration (FDA) has approved testosterone enanthate (Xyosted, Antares Pharma) subcutaneous injection for testosterone replacement therapy in men diagnosed with conditions ...

Xyosted carries a Boxed Warning regarding blood pressure increases that may potentially increase the risk for major adverse cardiovascular events. The Food and Drug Administration (FDA) has approved ...